• helpdesk@Lucintel.com
  • |
  • +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

The Impact of COVID-19 is included in HER2 Antibody Market. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry


The future of the global HER2 antibody market looks promising with opportunities in hospitals and medical centers. The global HER2 antibody market is expected to grow with a CAGR of 8%-10% from 2020 to 2025. The major drivers for this market are increasing prevalence of HER2 positive, rising awareness of personalized medicines, and increasing geriatric population.

A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global HER2 antibody market report, please download the report brochure.

 
 
HER2 Antibody Market by Type of Treatment Drug, Application and Sales Channel

 
In this market, transtuzumab is the largest type of treatment drug of HER2 antibody. Growth in various segments of the HER2 antibody market are given below:
 
 
HER2 Antibody   Market by Segments


 
The study includes trends and forecast for the global HER2 antibody market by type of treatment drug, application, sales channel, and region as follows:
 
By Type of Treatment Drugs [Value ($ Million) shipment analysis for 2014 – 2025]:
  • Trastuzumab
  • Lapatinib
  • Ado-trastuzumab Emtansine
  • Pertuzumab
  • Everolimus

By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
  • Hospitals
  • Medical Centers

By Distribution Channel [Value ($ Million) shipment analysis for 2014 – 2025]:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
  • North America
    • United States
    • Canada 
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
  • The Rest of the World
    • Brazil
 

Some of the HER2 antibody companies profiled in this report include Roche, Novartis, Abnova, Pfizer, InvivoGen, Biocon, Bio-Techne, Samsung Bioepis and Celltrion.
Lucintel forecasts that trastuzumab will remain the largest treatment drug type segment over the forecast period due to increasing prevalence of cancer.

North America will remain the largest region over the forecast period due to developed healthcare infrastructure and increasing awareness of population regarding the treatment of HER2 breast cancer in the region.



 
Features of the Global HER2 Antibody Market
 
  • Market Size Estimates: Global HER2 antibody market size estimation in terms of value ($M) shipment.
  • Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
  • Segmentation Analysis: Global HER2 antibody market size by various segments, such as type of treatment drug, application, and sales channel in terms of value.
  • Regional Analysis: Global HER2 antibody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type of treatment drug, application, sales channel, and region for the global HER2 antibody market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global HER2 antibody market.
  • Analysis of competitive intensity of the industry based on Porter’s Five Forces model.



 
This report answers following key questions
 
Q.1 What are some of the most promising potential, high-growth opportunities for the global HER2 antibody market by type of treatment drugs (trastuzumab, lapatinib, ado-trastuzumab emtansine, pertuzumab, and everolimus), application (hospitals and medical centers), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and others) and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global HER2 antibody market?
Q.5 What are the business risks and threats to the global HER2 antibody market?
Q.6 What are the emerging trends in this HER2 antibody market and the reasons behind them?
Q.7 What are some changing demands of customers in this HER2 antibody market?
Q.8 What are the new developments in this HER2 antibody market? Which companies are leading these developments?
Q.9 Who are the major players in this HER2 antibody market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this HER2 antibody market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global HER2 antibody market?

 


Report Scope


Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates)
2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Type of Treatment Drugs (Trastuzumab, Lapatinib, Ado-trastuzumab Emtansine, Pertuzumab, and Everolimus), Application (Hospitals and Medical Centers), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)

Regional Scope

North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)

Customization 10% Customization without Any Additional Cost

Table of Contents


1. Executive Summary

2. Market Background and Classifications
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2014 to 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global HER2 Antibody Market Trends and Forecast
3.3: Global HER2 Antibody Market by Type of Treatment Drugs
3.3.1: Trastuzumab 
3.3.2: Lapatinib
3.3.3: Ado-trastuzumab Emtansine
3.3.4: Pertuzumab
3.3.5: Everolimus
3.4: Global HER2 Antibody Market by Application
3.4.1: Hospitals
3.4.2: Medical Centers
3.5: Global HER2 Antibody Market by Distribution Channel
3.5.1: Hospital Pharmacies
3.5.2: Retail Pharmacies
3.5.3: Online Pharmacies
3.5.4: Others

4. Market Trends and Forecast Analysis by Region
4.1: Global HER2 Antibody Market by Region
4.2: North American HER2 Antibody Market
4.2.1: Market by Type of Treatment Drugs: Trastuzumab, Lapatinib, Ado-trastuzumab Emtansine, Pertuzumab, and Everolimus
4.2.2: Market by Hospitals and Medical Centers 
4.2.3: Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others 
4.2.4: The United States HER2 Antibody Market
4.2.5: The Canadian HER2 Antibody Market
4.2.6: The Mexican HER2 Antibody Market
4.3: European HER2 Antibody Market
4.3.1: Market by Type of Treatment Drugs: Trastuzumab, Lapatinib, Ado-trastuzumab Emtansine, Pertuzumab, and Everolimus 
4.3.2: Market by Hospitals and Medical Centers 
4.3.3: Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others 
4.3.4: The HER2 Antibody Market of United Kingdom
4.3.5: The German HER2 Antibody Market
4.3.6: The French HER2 Antibody Market
4.4: APAC HER2 Antibody Market
4.4.1: Market by Type of Treatment Drugs: Trastuzumab, Lapatinib, Ado-trastuzumab Emtansine, Pertuzumab, and Everolimus 
4.4.2: Market by Hospitals and Medical Centers 
4.4.3: Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others 
4.4.4: The Chinese HER2 Antibody Market
4.4.5: The Indian HER2 Antibody Market
4.4.6: The Japanese HER2 Antibody Market
4.5: ROW HER2 Antibody Market
4.5.1: Market by Type of Treatment Drugs: Trastuzumab, Lapatinib, Ado-trastuzumab Emtansine, Pertuzumab, and Everolimus 
4.5.2: Market by Hospitals and Medical Centers 
4.5.3: Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others 
4.5.4: Brazilian HER2 Antibody Market

5. Competitor Analysis
5.1: Market Share Analysis
5.2: Product Portfolio Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis

6. Cost Structure Analysis
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin

7. Growth Opportunities and Strategic Analysis
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global HER2 Antibody Market by Type of Treatment Drugs
7.1.2: Growth Opportunities for the Global HER2 Antibody Market by Application
7.1.3: Growth Opportunities for the Global HER2 Antibody Market by Distribution Channel
7.1.4: Growth Opportunities for the Global HER2 Antibody Market by Region
7.2: Emerging Trends in the Global HER2 Antibody Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global HER2 Antibody Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global HER2 Antibody Market
7.3.4: Certification and Licensing

8. Company Profiles of Leading Players
8.1: F. Hoffmann-La Roche AG 
8.2: Novartis AG
8.3: Abnova Corporation
8.4: Pfizer, Inc. 
8.5: InvivoGen
8.6: Biocon Limited
8.7: Bio-Techne
8.8: Samsung Bioepis
8.9: Celltrion, Inc.
8.10: Company 10
 
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: HER2 Antibody Market: Trends, Forecast and Competitive Analysis Full Report $ 4,850
150 - page report
Lucintel has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Below is a brief summary of the primary interviews that were conducted by job function for this report.
 

 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.